In a notable development within the pharmaceutical industry, a federal judge in Delaware has directed Sanofi’s legal team to reassess portions of a $1.2 million fee request. This scrutiny comes after successful litigation by the French pharmaceutical giant in a protracted patent dispute initiated by Amgen over cholesterol medication. The judge highlighted concerns with the “bells and whistles” accompanying Sanofi’s litigation costs. For a full briefing on this legal exchange, visit Law360.